Multifaceted Strategies for Hypertension Control in Low-Income Patients.

9 major claims checked against the paper's own evidence: 2 not fully backed by the presented evidence (unsupported or overstated).

Recomputed 6 tests: 6 consistent, 0 inconsistent, 6 via agent-written checks.

3 integrity concerns flagged (0 high).

8 copyedit issues flagged: mostly consistency, clarity, punctuation.

Checked 30 references: 27 verified — 3 not checked.

4 data/code links checked; 3 live.

The paper is ready for submission after addressing the pre-submission actions, particularly the critical and high-priority items. The most consequential gaps are the missing data availability statement and code repository, and the internal contradiction in the reported confidence intervals.

1. 1.
   HIGHdata code

   Add a data availability statement specifying a managed-access platform (e.g., Vivli, YODA) or a data access committee for individual patient data, with conditions and timeline.

   This is a required element for clinical trial reporting and its absence is a significant omission that could lead to rejection.
2. 2.
   HIGHdata code

   Deposit analysis code in a public repository (e.g., GitHub, Zenodo) with a persistent identifier and reference it in the manuscript.

   Code sharing is essential for reproducibility and is increasingly expected by journals.
3. 3.
   HIGHcopyedit

   Correct the 95% confidence intervals for the primary and secondary outcomes in the Results text to include the negative signs (e.g., change '9.0 to 3.8' to '-9.0 to -3.8' and '5.1 to 1.8' to '-5.1 to -1.8').

   This is a clear internal contradiction that could cause confusion and is a critical copyedit issue.
4. 4.
   HIGHethics

   Add an explicit statement of adherence to a recognized regulatory framework (e.g., Declaration of Helsinki) in the Methods or Ethics section.

   This is a standard expectation for clinical trials and its absence is a minor but notable reporting gap.
5. 5.
   HIGHreporting

   Temper the claim that the trial is 'the first to show' effectiveness in FQHCs, as the paper itself cites prior studies in this setting.

   Over-claiming novelty is a common reviewer objection and the evidence does not fully support this strong statement.
6. 6.
   HIGHreporting

   Temper the claim that the strategy is 'scalable to other primary care settings', as scalability was not directly tested.

   This claim goes beyond the data and could be seen as over-interpretation.
7. 7.
   HIGHreporting

   Reference the CONSORT statement for cluster-randomized trials in the Methods and include a completed checklist.

   This is a standard reporting guideline and its inclusion strengthens transparency.
8. 8.
   HIGHreporting

   Include a separate Conflicts of Interest section, even if none exist.

   This is a standard requirement for most journals and its absence is a minor gap.
9. 9.
   MEDIUMrigor

   Provide a list of specific antihypertensive medications used (or at least the most common ones) in a supplementary table.

   This improves reproducibility and is a standard expectation for intervention studies.
10. 10.
    MEDIUMrigor

    Specify the brand/model of the home blood pressure monitors given to patients.

    This improves reproducibility and is a standard expectation for intervention studies.
11. 11.
    MEDIUMrigor

    Include a brief statement on how outliers were handled in the statistical analysis, even if using robust methods.

    This addresses a minor gap in the study design reporting.
12. 12.
    LOWcopyedit

    Fix the typo 'credited' to 'accredited' in the Methods section.

    Minor copyedit issue.
13. 13.
    LOWcopyedit

    Ensure consistent spacing around '<' for p-values (e.g., 'P<0.001' to 'P < 0.001').

    Minor consistency issue.
14. 14.
    LOWcopyedit

    Complete the incomplete sentence in the Methods section: '( in the ).' should be '(details in the Supplementary Appendix).'

    Minor clarity issue.